$0.8061
Insights on Hookipa Pharma Inc.
Revenue is up for the last 3 quarters, 2.67M → 7.40M (in $), with an average increase of 34.1% per quarter
Netprofit is down for the last 3 quarters, -18.01M → -24.81M (in $), with an average decrease of 18.0% per quarter
In the last 1 year, Novo Nordisk A/s has given 52.5% return, outperforming this stock by 72.7%
In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 333.0%
5.79%
Downside
Day's Volatility :9.41%
Upside
3.85%
49.38%
Downside
52 Weeks Volatility :80.0%
Upside
60.49%
Period | Hookipa Pharma Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 15.03% | 0.5% | 0.0% |
6 Months | 83.62% | 11.7% | 0.0% |
1 Year | -20.19% | 6.2% | 2.2% |
3 Years | -93.55% | 13.5% | -23.0% |
Market Capitalization | 84.1M |
Book Value | $0.91 |
Earnings Per Share (EPS) | -0.86 |
Wall Street Target Price | 4.7 |
Profit Margin | 0.0% |
Operating Margin TTM | -244.76% |
Return On Assets TTM | -32.0% |
Return On Equity TTM | -84.81% |
Revenue TTM | 20.1M |
Revenue Per Share TTM | 0.21 |
Quarterly Revenue Growth YOY | -5.4% |
Gross Profit TTM | -53.0M |
EBITDA | -81.4M |
Diluted Eps TTM | -0.86 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.36 |
EPS Estimate Next Year | -0.51 |
EPS Estimate Current Quarter | -0.19 |
EPS Estimate Next Quarter | -0.12 |
What analysts predicted
Upside of 483.05%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 7.6M | - |
Net Income | -16.2M | ↑ 27.62% |
Net Profit Margin | -212.83% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 11.9M | ↑ 56.53% |
Net Income | -34.1M | ↑ 110.3% |
Net Profit Margin | -285.94% | ↓ 73.11% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 19.6M | ↑ 63.99% |
Net Income | -33.8M | ↓ 1.01% |
Net Profit Margin | -172.59% | ↑ 113.35% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 18.4M | ↓ 5.8% |
Net Income | -75.7M | ↑ 123.86% |
Net Profit Margin | -410.16% | ↓ 237.57% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 14.2M | ↓ 22.76% |
Net Income | -65.1M | ↓ 13.9% |
Net Profit Margin | -457.19% | ↓ 47.03% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 20.1M | ↑ 41.27% |
Net Income | -81.6M | ↑ 25.23% |
Net Profit Margin | -405.29% | ↑ 51.9% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.2M | ↓ 18.79% |
Net Income | -15.6M | ↓ 4.82% |
Net Profit Margin | -698.07% | ↓ 102.44% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 7.8M | ↑ 251.03% |
Net Income | -12.5M | ↓ 19.44% |
Net Profit Margin | -160.19% | ↑ 537.88% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.2M | ↓ 59.43% |
Net Income | -19.9M | ↑ 58.57% |
Net Profit Margin | -626.1% | ↓ 465.91% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.7M | ↓ 15.65% |
Net Income | -18.0M | ↓ 9.4% |
Net Profit Margin | -672.49% | ↓ 46.39% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 6.9M | ↑ 156.33% |
Net Income | -19.1M | ↑ 5.83% |
Net Profit Margin | -277.65% | ↑ 394.84% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.4M | ↑ 7.86% |
Net Income | -24.8M | ↑ 30.17% |
Net Profit Margin | -335.06% | ↓ 57.41% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 68.3M | ↓ 7.43% |
Total Liabilities | 23.9M | ↓ 79.51% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 143.7M | ↑ 110.61% |
Total Liabilities | 25.8M | ↑ 8.36% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 187.8M | ↑ 30.66% |
Total Liabilities | 31.7M | ↑ 22.63% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 126.0M | ↓ 32.89% |
Total Liabilities | 36.5M | ↑ 15.02% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 170.5M | ↑ 35.23% |
Total Liabilities | 67.9M | ↑ 86.37% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 161.3M | ↓ 5.35% |
Total Liabilities | 71.5M | ↑ 5.22% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 151.5M | ↓ 12.01% |
Total Liabilities | 38.2M | ↓ 5.17% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 170.5M | ↑ 12.49% |
Total Liabilities | 67.9M | ↑ 77.95% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 163.1M | ↓ 4.32% |
Total Liabilities | 79.6M | ↑ 17.18% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 191.1M | ↑ 17.18% |
Total Liabilities | 78.8M | ↓ 1.04% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 164.0M | ↓ 14.18% |
Total Liabilities | 69.0M | ↓ 12.47% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 161.3M | ↓ 1.63% |
Total Liabilities | 71.5M | ↑ 3.66% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -15.0M | ↑ 25.9% |
Investing Cash Flow | -2.2M | ↑ 65.77% |
Financing Cash Flow | 6.9M | ↓ 88.33% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -41.7M | ↑ 178.24% |
Investing Cash Flow | -2.0M | ↓ 7.02% |
Financing Cash Flow | 109.8M | ↑ 1496.84% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -39.3M | ↓ 5.73% |
Investing Cash Flow | -2.4M | ↑ 18.61% |
Financing Cash Flow | 73.4M | ↓ 33.1% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -66.0M | ↑ 67.81% |
Investing Cash Flow | -12.6M | ↑ 430.62% |
Financing Cash Flow | -235.0K | ↓ 100.32% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -20.0M | ↓ 69.71% |
Investing Cash Flow | -5.0M | ↓ 60.12% |
Financing Cash Flow | 72.3M | ↓ 30853.62% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -16.5M | ↓ 10.08% |
Investing Cash Flow | -958.0K | ↓ 41.3% |
Financing Cash Flow | 127.0K | ↓ 104.3% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 13.1M | ↓ 179.58% |
Investing Cash Flow | -599.0K | ↓ 37.47% |
Financing Cash Flow | -196.0K | ↓ 254.33% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.8M | ↓ 121.68% |
Investing Cash Flow | -274.0K | ↓ 54.26% |
Financing Cash Flow | -735.0K | ↑ 275.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -19.3M | ↑ 578.83% |
Investing Cash Flow | -445.0K | ↑ 62.41% |
Financing Cash Flow | 45.8M | ↓ 6333.33% |
Sell
Neutral
Buy
Hookipa Pharma Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Hookipa Pharma Inc. | 12.11% | 83.62% | -20.19% | -93.55% | -94.24% |
Moderna, Inc. | -1.15% | 39.75% | -18.77% | -40.22% | 304.34% |
Regeneron Pharmaceuticals, Inc. | -7.56% | 12.46% | 14.48% | 77.72% | 159.17% |
Novo Nordisk A/s | -2.8% | 32.13% | 52.48% | 239.51% | 414.16% |
Vertex Pharmaceuticals Incorporated | -4.96% | 10.08% | 23.01% | 83.3% | 130.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Hookipa Pharma Inc. | NA | NA | NA | -0.36 | -0.85 | -0.32 | NA | 0.91 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Hookipa Pharma Inc. | Buy | $84.1M | -94.24% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 304.34% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 159.17% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 414.16% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.08% | 28.81 | 36.68% |
Baker Bros Advisors LP
Artal Group S A
Knoll Capital Management LP
EcoR1 Capital, LLC
FMR Inc
Alyeska Investment Group, L.P.
Hookipa Pharma Inc.’s price-to-earnings ratio stands at None
Read Morehookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a
Organization | Hookipa Pharma Inc. |
Employees | 151 |
CEO | Mr. Joern Aldag |
Industry | Pharmaceuticals: Major |